Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response (DDR) therapy market that is distinct from established PARP inhibitor therapies.
Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph causal AI platform to support patient stratification, clinical trial design and oncology evidence generation.
Ongoing CMC, IND-enabling and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies. The company’s strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations and integrated development capabilities.
In recent years, Onco-Innovations has expanded its operational footprint through acquisitions and research partnerships. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
InvestorWire, a specialized communications platform, is distributing this press release. For more information, visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Onco-Innovations Advances Novel PNKP Inhibitor ONC010, Targeting DNA Repair Pathways in Cancer.